Historically, the first ADC-HER2 put on the market was trastuzumab emtansine or TDM-1, whose interest in HER2+ breast cancers has been widely demonstrated whether in metastatic [16,17,18], adjuvant [19,20], or neoadjuvant [21] settings. This evidence concerns the gene ERBB2 and breast carcinoma.